Results 121 to 130 of about 654,754 (303)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

The Cost of Preanalytical Errors in the Context of Inpatient Complete Blood Count Testing

open access: yes, 2013
The majority of laboratory testing errors originate in the pre-analytical phase. While the causes and frequencies of pre-analytical errors are well characterized, there are few studies investigating the cost of these errors.
Burrows, James Michal
core   +1 more source

Misidentification and other preanalytical errors [PDF]

open access: yesJournal of Medical Biochemistry, 2008
The largest number of laboratory errors occur in the preanalytical phase and are mainly due to educational and organizational reasons. The experience of our institution, as well as the results of an Italian interlaboratory effort to detect and reduce ...
Bonini Pierangelo   +3 more
doaj  

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Study of Preanalytical errors in hematology laboratory of a tertiary care hospital

open access: yes, 2017
Laboratories play an important role in the diagnosis and management of the disease. Errors are part and parcel of human nature. Its human tendency to make errors.
Dhiraj kumar B.Shukla   +2 more
core   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Preventing laboratory error and improving patient safety – The role of non-laboratory trained healthcare professionals

open access: yesClinical Infection in Practice
In 2023, the World Health Organization estimates that 1 in every 10 patients experiences harm from unsafe care, with 3 million deaths occurring yearly from the same. Over half the cases of patient harm are preventable and resultant from errors. As 70% of
John C. Lam, Deirdre L. Church
doaj   +1 more source

Correction of Force Errors for Flexible Manipulators in Quasi-Static Conditions [PDF]

open access: yes, 1990
This paper deals with the problem of controlling the interactions of flexible manipulators with their environment. For executing a force control task, a manipulator with intrinsic (mechanical) compliance has some advantages over the rigid manipulators ...
Bicchi, Antonio   +3 more
core  

Errors in a Stat Laboratory: types and frequencies 10 years later.

open access: yes, 2007
BACKGROUND: In view of increasing attention focused on patient safety and the need to reduce laboratory errors, it is important that clinical laboratories collect statistics on error occurrence rates over the whole testing cycle, including pre-, intra-
Carraro P   +3 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy